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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S425donors. Many of these proteins are cartilage speciﬁc proteoglycans such
as hyaluronan and proteoglycan link protein 1, aggrecan core protein or
lumican as well as some proteins with a well-known role in the
pathogenesis of OA like COMP or MMP3. On the other hand, 21 proteins
exhibited a signiﬁcantly reduced abundance in OA patients when
compared to controls. Interestingly, we detected several proteins which
belong to the tenascin protein family, like tenascin-X, which accelerates
collagen ﬁbril formation. We also found WISP2 decreased at day 14,
suggesting a lower activity of the Wnt signaling pathway in OA cells.
Conclusions: The identiﬁcation and quantiﬁcation of these secreted
proteins enhance our knowledge on the extracellular regulation of the
chondrogenesis and allow the identiﬁcation of extracellular markers of
this process. Moreover, the lower expression of some of them in OA
patients (like tenascin-X or WISP2), suggest their putative usefulness
for the molecular monitorization of the chondrogenesis in cell therapy-
based approaches for cartilage repair.
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A LIPIDOMIC STUDY OF SPHINGOLIPID SPECIES IN HUMAN
SYNOVIAL FLUID
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Purpose: Articular synovial ﬂuid (SF) is a complex mixture of compo-
nents either derived from plasma or locally synthesized by synovial
tissues, which are involved in nutrition, communication, shock
absorption, and lubrication. Alterations in its composition can be
associated with increased friction, leading to articular cartilage damage,
or with changes in inﬂammatory status of synovial joints. We already
quantiﬁed 130 phospholipid species in human osteoarthritis (OA) and
rheumatoid arthritis (RA) SF. The presented lipidomic investigation
aims to quantify for the ﬁrst time, the composition of sphingolipids
[sphingomyelins (SM), ceramides (Cer), hexosylceramides (HexCer) and
dihexosylceramides (Hex2Cer) species] in the SF of knee joints from
unaffected controls, patients with early (eOA) and late (lOA) stages of
OA and from RA patients, and to further elucidate whether the con-
centrations of individual lipid species are associated with the stage of
OA disease.
Methods: According to predeﬁned inclusion and exclusion criteria
patients were included in the study. The use of human SF for this study
was approved by the local ethics committee of our university, and all
participants provided written informed consent. Lipids were extracted
from SF without cells and cellular debris from 9 postmortem donors
(control), 18 RA, and 30 OA patients. OA group was subcategorized as
early (n ¼ 17) and late (n ¼ 13) using Outerbridge score. RA patients
were classiﬁed according to the criteria of the American College of
Rheumatology. Lipids were quantiﬁed using electrospray ionization
tandem mass spectrometry - directly or coupled with hydrophilic
interaction liquid chromatography. The quantitative values of all lipid
species were corrected by the method described by Kraus et al. (2002).
The Kruskal-Wallis test adjusted with a false discovery rate (FDR) of 10%
and the Wilcoxon rank sum test were applied to determine statistically
signiﬁcant differences. P values < 0.05 were considered to be statisti-
cally signiﬁcant.
Results: We provide a novel, detailed overview of sphingolipid species
in human SF. The analytical set-up used in the present study allowed us
to quantitate 35 different sphingolipid species. We identiﬁed 19 SM
species, based on the length and saturation of the attached fatty acids.
SM 34:1 was the predominant species among SMs. In addition, versus
control SF, all species were elevated in eOA, lOA and RA SF. Remarkably,
all SM species rose approximately 2-fold in SF from eOA to lOA and
approximately 1.5-fold in SF from eOA to RA. However, we found no
signiﬁcant different levels of SM species in lOA compared with RA SF.
Also, 6 Cer, 5 HexCer and 5 Hex2Cer were identiﬁed in human SF. Cer
d18:0/24 was the predominant species. Moreover, most Cer species
contained saturated fatty acids in all cohorts. Compared to control SF,
the levels of most Cer species were 4.5-fold higher in lOA and 5.8-fold in
RA SF. Moreover, all Cer species rose approximately 1.7-fold in SF from
eOA to RA, and nearly 1.3-fold in SF from lOA to RA.
Conclusions: This lipidomic investigation present for the ﬁrst time a
detailed overview of sphingolipid species in human SF. Compared to
control SF the concentrations of sphingolipid species such as SM andCer were found to be elevated in eOA, lOA and RA SF. Since, disease and
stage-dependent differences in the composition and concentrations of
lipid species might result not only in an impaired lubrication but also in
an altered inﬂammatory status of joints, sphingolipids appear to be
associated with the pathogenesis of OA and RA. Our study lays the
foundation for addressing speciﬁc questions regarding the biosynthesis
and function of sphingolipid species in SF.
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Purpose: Osteoarthritis (OA) is characterized by the loss of structural
components from the extracelullar matrix (ECM) of articular cartilage.
The progressive release of proteins from the tissue and an abnormal
metabolic activity can be speciﬁcally detected by the immune system,
leading to a humoral immune response producing immunoglobulins
against these proteins (autoantibodies). Autoantibodies are stable cir-
culating proteins, easily measurable in serum, and may be the signature
before clinical manifestations of the disease. Protein microarrays have
emerged providing a tool for the identiﬁcation of disease immuno-
signatures. The aim of this study was to detect the presence of auto-
antibodies in OA serum samples and compare these results with those
obtained from healthy (CTRL) and rheumatoid arthritis (RA) sera.
Methods: Antibodies were detected using an speciﬁc Nucleic Acid
Protein Programmable Array (NAPPA) designed and constructed as
previously described by Ramachandran et al. 2008, containing 80
sequence-veriﬁed full-length human genes obtained from the Center
for Personalized Diagnostics at the Arizona State University (www.
dnasu.org). Once protein was displayed by in situ protein expression
system, NAPPA arrays were incubated in optimized conditions with 20
OA, 20 RA and 18 CTRL serum samples. The autoantibodies were
detected by anti-human IgG-HRP and ﬂuorescence dye. Array images
were obtained and processed by Genepix4000B and GenePix Software
6.0. For data analysis, background correction was performed by sub-
traction of the ﬁrst quartile of non-DNA spots intensity and then divided
the excess intensity by the median of spots without DNA across arrays.
Results: Signiﬁcantly (p< 0.05) 4 different expression of autoantibodies
against four different proteins has been observed between OA and CTRL
serum samples. Of note, 2 of these proteins are related to the metabo-
lism of ECM; the others are associated to cell adhesion (1) and bone
mineralization (1). Most interestingly, this approach allowed the dif-
ferential classiﬁcation of RA and OA patients by the detection of 3
speciﬁc autoantibodies against proteins involved in cell proliferation
and bone mineralization processes; one of these proteins also dis-
tinguishing between CTRL and RA subjects.
Conclusions: We have identiﬁed the presence of speciﬁc autoanti-
bodies in OA allowing to distinguish between OA and CTRL patients and
most interestingly, between OA and RA patients. These autoantibodies
released to the serum might have a biomarker value to more accurate
early diagnosis and prognosis of OA patients in clinical routine.
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PEPTIDES PROFILING OF CARTILAGE SECRETOME: A PROMISING
ALTERNATIVE FOR OA BIOMARKER DISCOVERY
V. Calamia, L. Lourido, J. Mateos, P. Fernandez-Puente, C. Fernandez,
B. Rocha, F.J. Blanco, C. Ruiz-Romero. Rheumatology Div., Proteomics
Group-ProteoRed/ISCIII, INIBIC-CHUAC, A Coru~na, Spain
Purpose: The low-molecular-weight subset of the cartilage proteome
(also termed cartilage peptidome) may have a diagnostic potential in
osteoarthritis (OA) research, not yet fully exploited. The aim of this
study is to investigate the cartilage secretome by means of peptidomic
analysis and to provide a novel source for OA biomarker discovery.
Methods: Tissue explants were obtained from the dissection of human
OA cartilages, both from the unwounded zone (UZ) and the wounded
zone (WZ). The study was approved by the local ethical committee.
Cartilage shavings from each zone were cut into 6 mm discs and ﬁve
Table 1
A panel of different types of potential protein biomarkers of OA
Protein name Symbol Ratio
UZ/N
p value Ratio
WZ/N
p value OA biomarker
type
Annexin A5 4,8753 0,0387 1,2706 0,5217 Early
Chitinase-3-like
protein 2
CHI3L2 4,8306 0 0,871 0,147 Early
Phospholipase A2 4,4463 0,0308 0,3373 0,2114 Early
Hyaluronan and
proteoglycan
link protein 1
HPLN1 2,3768 0 1,0375 0,1073 Early
Apolipoprotein A-I APOA1 2,884 0,1025 7,7268 0 Late
Apolipoprotein E APOE 1,5417 0,9203 4,6989 0,0248 Late
Complement C3 C3 0,9908 0,8541 2,6303 0,0097 Late
Complement C4-B C4B 1,2942 0,7081 2,3121 0,0151 Late
Haptoglobin HPT 6,9823 0,0432 14,3219 0,0001 Progression
Histone H4 H4 2,355 0,0196 7,2444 0,0198 Progression
Tenascin TENA 9,6383 0,0001 27,7971 0 Progression
TGF-b-induced
protein ig-h3
BIGH3 7,7268 0 11,695 0 Progression
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CO2) in serum-free DMEM up to 6 days. Conditioned media from each
condition were collected at day 1, 3 and 6. Selective extraction of
endogenous peptides was accomplished by combining ultraﬁltration
and solid phase extraction. Then, the peptides were directly analyzed by
nano reversed-phase liquid chromatography (RP-LC) in an Easy nLC II
system coupled to an ion trap LTQ Orbitrap Velos Pro mass spec-
trometer (Thermo Scientiﬁc). Peptide/protein identiﬁcations were
searched against database (human_fasta) using the SEQUEST algorithm
(Proteome Discoverer 1.3, Thermo Scientiﬁc).
Results: After optimization steps of the procedure, day 3was selected as
the best point for our proteomic analysis to compare the peptide pro-
ﬁles from UZ and WZ, showing the highest number of unique peptides/
proteins and the lowest serum contamination. Globally, this study led to
the identiﬁcation of a panel of 262 peptides corresponding to 36 pro-
teins that were differentially released from the UZ and WZ in OA car-
tilage. 60 peptides (corresponding to 20 proteins) were detected only in
the UZ (early biomarkers), while 18 peptides (corresponding to 5 pro-
teins) only in the WZ (late biomarkers). Finally, 11 proteins were
detected in both zones; however also in this case the number of pep-
tides was higher in the UZ than in the WZ. These results suggest that
cartilage from the UZ shows a protein turnover rate higher than carti-
lage from theWZ, thus facilitating the discovery of OA biomarkers in an
early stage of the disease, when radiographic signs are not yet detect-
able. Data mining revealed that most of the identiﬁed proteins were
cartilage ECM proteins or proteins with well-established matrix func-
tions, such as collagens and proteoglycans, thus indicating the high
cartilage-speciﬁc biomarker concentration present in our samples.
Some of these proteins have been associated with OA pathology before
(collagen II, proteoglycan 4, tubulin, vimentin), while others are
described here for the ﬁrst time (augurin, salivary acidic proline-rich
phosphoprotein 1/2, dermcidin).
Conclusions: Our results clearly indicate that proﬁling of peptides from
cartilage secretome represents a promising alternative in the ﬁeld of OA
biomarker discovery. In this study we highlight its potential application
as novel OA biomarker source both for early disease detection (early
biomarkers) and for monitoring disease progression (late biomarkers).
Further investigations of these peptides on biological ﬂuids will assess
their biomarker usefulness.
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Purpose: Osteoarthritis (OA) is characterized by the progressive loss
of cartilage structural extracellular matrix (ECM) components,
mainly collagenous and non-collagenous proteins. The release of
these proteins from the tissue can vary according to the stage of the
disease. Characterization of molecular differences between
cartilage subtypes will provide a background for a better under-
standing of OA onset and progression. The aim of this study was to
perform a quantitative proteomics approach to identify and quantify
those proteins released from normal (N) and OA human articular
cartilages.
Methods: Tissue explants were obtained from the dissection of 4 N
and 4 OA cartilages, both from femoral heads and tibial condyles.
Among the OA samples, we differentiated the wounded zones (WZ)
from those corresponding to the area adjacent to the lesion, or
unwounded zones (UZ). The study was approved by the local ethical
committee. Cartilage shavings from each donor were cut into 6 mm
discs and ﬁve discs/donor were placed into 96-well plates and
incubated during 6 days (37C/5% CO2). The conditioned media from
each condition were collected and their proteins were digested with
trypsin. Each peptide mixture was labelled with different isobaric
tags using the iTRAQ reagents (ABSciex). Then, labelled peptides of
the different conditions were mixed, desalted and separated by liq-
uid chromatography (LC). The resulting fractions were grouped and
resolved by reversed-phase nano-LC coupled to mass spectrometry
(MS). The identiﬁcation and relative quantiﬁcation of the proteins
was carried out with Protein Pilot 3.0 software.
Results: Globally we were able to identify 402 proteins released from
the cartilage explants. Measurement of the different iTRAQ tagsintensities allowed the relative quantiﬁcation of almost all of them (n
¼ 390). After statistical analysis we found 104 secreted proteins
showing differences in abundance (0.8 ratio 1.2, p 0.05)
between the different OA zones (WZ and UZ) and N samples. We
classiﬁed them into 3 sets of proteins: a ﬁrst group of 11 proteins
modulated speciﬁcally in UZ sample; a second group of 38 proteins
altered only in WZ samples, and ﬁnally a third group of 55 proteins
modiﬁed in both OA zones. Proteins increased in UZ samples are
classiﬁed as early OA biomarkers, while proteins increased only in
WZ samples are deﬁned as late OA biomarkers (Table 1). Proteins
showing a gradual increase among OA samples are indicated as
progression biomarkers (Table 1). Although some of these proteins
had a previously reported putative biomarker value for OA, most of
them are novel candidates of the disease onset (the ﬁrst group) and
progression (the second and third groups). Interestingly, when we
compared these results with those obtained from cartilage tissue
extracts we found that most of the proteins increased in OA cartilage
secretomes (like HPLN1, TENA, and BIGH3) are decreased in cartilage
proteomes and viceversa. Furthermore, some of these modulations
conﬁrmed the results obtained in OA serum in a previous work by
our group (e.g. APOE, C3, and HPT).
Conclusions: We describe a novel panel of cartilage secreted proteins
with potential biomarker value. This panel is now being explored in
biological ﬂuids (synovial ﬂuid and serum) for the development of early
diagnosis and/or anti-OA therapy monitoring strategies.Regenerative medicine
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CHONDROGENESIS OF HUMAN SYNOVIUM-DERIVED MESENCHYMAL
STEM CELLS INDUCED BY KARTOGENIN AND TRANSFORMING
GROWTH FACTORS
D. Shi, X. Xu, Q. Jiang. Sports Med. and Adult Reconstruction, Nanjing,
China
Purpose: To investigate if small molecule compound Kartogenin (KGN)
can direct the differentiation of human synovium derivedmesenchymal
stem cells (SMSCs) into chondrocytes or increase the chondrogenic
potential of tranforming growth factors.
Methods: Human SMSCs were isolated from synovial membrane tissue
harvested from 6 donors when they underwent total knee arthroplasty.
5  105 cells were centrifuged to form pellets and then incubated in
control medium or chondrogenic medium. The chondrogenic medium
was consisted of transforming growth factors with or without addition
of KGN. The group inwhich pellets induced only by KGNwas also setted.
We also designed a group in which SMSCs were induced ﬁrst with TGF-
b3 for 1 week and then with KGN for 2 weeks. Pellets were induced for
21 days. Pellets size, hematoxylin and eosin staining, immunohis-
tochemical staining for collagen type II, and cartilage speciﬁc gene
epression were used to measure chondrogenic ability.
